Skip to main content
Premium Trial:

Request an Annual Quote

ValiGene, Kimeragen Merge To Create New Functional Genomics Co., ValiGen

Premium

N

EWTOWN, Pa.--Kimeragen here and ValiGene of Paris announced that they will merge to create ValiGen, a functional genomics company that will combine the genomics platform under development at ValiGene with chimeraplasty, the gene correction technology being developed at Kimeragen. The new company will apply genomics and chimeraplasty technologies to identify and validate novel targets for therapeutic intervention against major diseases, both for commercial partners and for itself. ValiGen will explore the potential for chimeraplast-based gene repair therapeutics to treat human diseases associated with particular mutations and also investigate agricultural applications. The merged company will have approximately 100 employees at operations here and in Paris.

Filed under

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.